Published

Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Molecular Psychiatry
Date: 2026-07-27
Source: Europe PMC
DOI: 10.1038/s41380-026-03777-z
PubMed: 42521762

Derived topics and classifications

psilocybin Depression Mechanism of Action Receptor Pharmacology Biomarkers Healthy Volunteers Treatment-Resistant Depression Transcriptomics Proteomics Immune Function Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.2026-07-27

Related papers

Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?Research Directions Depression · 2023-10-12 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-18 Psilocybin may help cancer patients with depression and anxiety for yearsAccess Science · 2019-12-31 The Utility of Psilocybin in Managing Anxiety and Depression in Cancer PatientsBiochemistry and Molecular Biology Education · 2018-07-31 Can Psilocybin Treat Severe DepressionJournal watch · 2017-11-02 Psilocybin to Manage Cancer-Related DepressionUnknown journal · 2016-12-20